Global Cancer Biomarkers Market Size, Growth, Opportunity and Forecast 2022-2030

  • Product Code:
    RP-ID-10008242
  • Published Date:
    27 Sep 2021
  • Region:
    Global
  • Pages:
    145
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-12

Impact Analysis on the Growth of Market

Inflation and Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

..

..

The Research Report is Updated with 2021 Base Year, 2022 Estimated year and Forecast till 2031 with Market Insights.


With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2021 as base year, 2022 as estimated year and forecast to 2031. This will have market drivers, recovery rate in the market, insights and competitive analysis.



Market Overview:

Translate Report

" The global cancer biomarkers market is estimated to be ~USD 18 billion by the end of 2021 and is expected to expand at a CAGR of ~12% over the period 2022-2030. Cancer is the second leading cause of death in the United States after heart disease due to positive growth in this market. In the United States, the prevalence of breast, prostate, and lung malignancies is increasing rapidly, with approximately 1,600 cases per year. In 2017, there were approximately 200,000 cases of breast cancer in the United States.


Patients and healthcare professionals are increasingly aware of the importance of early diagnosis of malignant tumors, and the growing demand for personalized medicine is expected to provide huge growth opportunities for this cancer biomarker market in the next decade.

 
Diagnostic biomarkers used for early diagnosis enable doctors to decide on better treatment alternatives and thus a successful recovery in a shorter time. In addition, it is estimated that increased regulatory approvals for new drugs and diagnostic methods related to cancer biomarkers will increase the adoption rate. 


For example, in 2016, Epigenomics AG, a company involved in the development of new epigenetic biomarker tests, announced that the Chinese government would use its Epi proColon to detect colorectal cancer (CRC).

 

TYPE INSIGHTS: 


According to type, the market is divided into breast, prostate, colorectal, cervix, liver and lung. Breast cancer is the biggest part of 2020. Breast cancer, lung cancer and prostate cancer accounted for more than 38% of revenue in 2016. Increasing awareness of early detection and growing population base targets are key factors contributing to dominance. 

 

Lung cancer is expected to grow the fastest in the prognosis period. More and more diagnostic tests for EGFR and BRAF mutations are used as important biomarkers for the diagnosis of non-small cell lung cancer, which are expected to promote the growth of the market segment.

 

BIOMOLECULAR INFORMATION: 


Based on biomolecules, the market is further subdivided into genetic, epigenetic, metabolic and proteomic biomarkers. Genetic biomarkers occupy a considerable market share due to their wide range of uses, high reliability, and easy analysis. According to reports, more than 85% of malignant tumors are detected with the help of genetic and proteomic biomarkers. 

 

Epigenetics has been widely recognized in the field of cancer diagnosis. Many participants are conducting extensive research to analyze key epigenetic modifications related to cancer in order to further develop biomarkers for targeted drugs. Increased cooperation between pharmaceutical companies in the development of new drugs for epigenetic biomarkers is expected to drive growth in this area.

 

 APPLICATION INFORMATION: 


Cancer biomolecules have applications in various fields, including drug discovery and development, diagnosis and personalized medicine. Diagnosis is a major revenue-generating market application, related to factors such as the continuous development of biomarker-based cancer tests with high specificity and sensitivity. 

 

Due to its growing demand and growing awareness among healthcare professionals, it is expected to witness a booming growth rate. In addition, the approval of more and more complementary diagnostic tests for cancer drugs is expected to affirm the market growth.

 

REGIONAL OUTLOOK:


North America dominates the regional market, followed by Europe. The high adoption of innovative technologies, the existence of key pharmaceutical companies, the established R&D infrastructure related to the development of new diagnostic products, and the growing demand for early and targeted diagnosis are the main factors in the above-mentioned areas. 

 

An enabling environment for cancer screening, clinical trials, and increased government funding to support drug development programs are expected to achieve a lucrative compound annual growth rate during the forecast period. In addition, the growing attention of pharmaceutical companies in the region, coupled with increasing awareness of biomarker-based diagnostics, is one of the important drivers of growth.

 

 CANCER BIOMARKER MARKET SHARE OUTLOOK:

 
 Abbott Laboratories; F. Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific; Affymetrix; Illumina, Inc.; Agilent Technologies; Merck; Hologic, Inc .;Huaxia Biological Co., Ltd.; Becton, Dickinson and Company are some of the major players in the market. The development of new products, cooperation with research institutions to develop new biomarkers, and mergers and acquisitions of small companies are key strategies for these companies to achieve stability and stability. market status.

 

  SECTORS COVERED IN THIS REPORT: 


This report forecasts global, regional and national sales growth and provides an analysis of industry trends in each sub-sector from 2022-2030. In this study, Kenneth Research presents Global Bio I looked into cancer, a marker market. and Molecular Viability, Types, Uses and Sectors: Forecast Type (Sales, $1 Billion, 2022-2030) Breast Cancer, Prostate Cancer, Major Colorectal Cancer, Uterine Cancer, Liver Cancer, Lung Cancer, etc. (Revenue, $1 Billion). 2022-2030) Research and development of other personalized medical diagnosis. "
 


Geography Analysis:


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

1. Thermo Fisher Scientific
2. Bio-Rad Laboratories
3. Roche Diagnostics
4. Qiagen N.V.
5. Illumina
6. GE Healthcare
7. Agilent Technologies
8. Biomérieux SA
9. Merck & Co.
10. Abbott Laboratories
11. Becton, Dickinson and Company
12. Danaher Corporation
13. Myriad Genetics
14. Sysmex Corporation
15. Hologic
16. Quest Diagnostics

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports

-->